MRNS
$18.69
Marinus Pharma CS
$.71
3.95%
MRNS
Earnings Whisper ®
N/A
2nd Quarter June 2021
Consensus:  ($0.66)
Revenue:  $2.70 Mil
Monday
Aug 16
7:30 AM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when MRNS reports earnings?
Beat
Meet
Miss

Where is MRNS's stock price going from here?
Up
Flat
Down
Stock chart of MRNS
Analysts
Summary of analysts' recommendations for MRNS
Score
Grade
Pivots
Resistance
$20.01
$19.36
$19.02

$18.38

Support
$18.04
$17.39
$17.06
Tweet
Growth
Description
Marinus Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It is focused on developing and commercializing therapeutics for the treatment of epilepsy and other targeted neurological, behavioral and psychiatric disorders. The Company offers Ganaxolone which has completed Phase II clinical trial for the treatment of patients with refractory focal onset seizures. Marinus Pharmaceuticals, Inc. is headquartered in New Haven, Connecticut.
Peers
InterCeptBioMarin PharmaceuticalVertex PharmaceuticalsZoetisUltragenyx PharmaceuticalRegeneron PharmaceuticalsBristol-Myers SquibbPfizerEli LillyMerck & Co.